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Abstract
Since 2013, federal research-funding agencies have been required to develop and implement broad data sharing
policies. Yet agencies today continue to grapple with the mechanisms necessary to enable the sharing of a wide range
of data types, from genomic and other -omics data to clinical and pharmacological data to survey and qualitative data.
In 2016, the National Cancer Institute (NCI) launched the ambitious $1.8 billion Cancer Moonshot Program, which
included a new Public Access and Data Sharing (PADS) Policy applicable to funding applications submitted on or
after October 1, 2017. The PADS Policy encourages the immediate public release of published research results and
data and requires all Cancer Moonshot grant applicants to submit a PADS plan describing how they will meet these
goals. We reviewed the PADS plans submitted with approximately half of all funded Cancer Moonshot grant
applications in fiscal year 2018, and found that a majority did not address one or more elements required by the PADS
Policy. Many such plans made no reference to the PADS Policy at all, and several referenced obsolete or outdated
National Institutes of Health (NIH) policies instead. We believe that these omissions arose from a combination of
insufficient education and outreach by NCI concerning its PADS Policy, both to potential grant applicants and among
NCI’s program staff and external grant reviewers. We recommend that other research funding agencies heed these
findings as they develop and roll out new data sharing policies.

Policy Significance Statement
Federal research-funding agencies must take into account the practical challenges inherent in promulgating broad
new data sharing policies and mechanisms. This study identifies several implementation issues that hampered the
rollout of National Cancer Institute (NCI)’s Cancer Moonshot Public Access and Data Sharing (PADS) Policy. The
lessons learned by NCI should be applied to other agencies that are developing new data sharing policies, particularly
as NIH considers a new agency-wide data sharing policy that would apply across all NIH institutes and centers.

Abbreviations
CC, creative commons; CEDR, Cancer Epidemiology Data Repository; dbGaP, Database of Genotypes
and Phenotypes; DMS, Data Management and Sharing; GDC, Genomic Data Commons; HGP, Human
© The Author(s), 2020. Published by Cambridge University Press in association with Data for Policy. This is an Open Access article, distributed under
the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written
permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
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Genome Project; NCI, National Cancer Institute; NHGRI, National Human Genome Research Institute;
NIH, National Institutes of Health; OMB, Office of Management and Budget; PADS, Public Access and
Data Sharing; TCIA, The Cancer Imaging Archive.
Introduction
In 2016, the National Cancer Institute (NCI), the largest research funding organization within the
U.S. National Institutes of Health (NIH), launched the ambitious $1.8 billion Cancer Moonshot Program
to accelerate innovative cancer research and advance cancer therapies and treatments. One of the key
elements of the Cancer Moonshot Program, and of all cancer research today, is the generation of data. As
one commentator notes, “[u]nderstanding cancer is understanding cancer’s information” (Sherkow, 2018,
p. 301). And in order to ensure that the value of this data is maximized, and to overcome any inherent
reluctance by cancer researchers to share their data, the Cancer Moonshot Program expressly encourages
the broad sharing of data among researchers and the public (Cancer Moonshot Blue Ribbon Panel Report,
2016; Mattioli, 2017; Sherkow, 2018).
Key to the Cancer Moonshot Program was a new Public Access and Data Sharing (PADS) Policy
(National Cancer Institute (NCI), 2017a; Department of Health & Human Services (HHS), 2017). The
PADS Policy is applicable to all Cancer Moonshot funding applications submitted on or after October
1, 2017. It encourages the immediate public release of published research results and data and requires all
Cancer Moonshot grant applicants to submit a PADS plan describing how they will meet these goals.
The PADS Policy is ambitious in that it extends data sharing principles that originated in the realm of
genomics to all aspects of cancer research, from cell biology and pathology to chemotherapy and surgery
to patient communication and psychology. But despite this sweeping mandate, little detail was provided in
the Policy regarding data sharing practices and practicalities, particularly in research areas outside of
cancer genetics and genomics. Informally, we observed that numerous cancer researchers funded by the
Cancer Moonshot Program were perplexed by the requirements of the PADS Policy.
We thus sought to gain a better understanding of how cancer researchers understood and sought to
comply with the PADS Policy requirements. To that end, we analyzed the PADS plans submitted with
approximately half of all funded Cancer Moonshot grant applications in fiscal year 2018. We found that a
majority of these researcher-generated plans did not address one or more elements required by the PADS
Policy. Many plans made no reference to the PADS Policy at all, and several referenced obsolete or
outdated NIH policies instead.
In the remainder of this article, we discuss the background data sharing requirements and policies that
led to the Cancer Moonshot PADS Policy, as well as the specific requirements of the PADS Policy itself.
We then describe the study that we conducted of submitted PADS plans and our findings. We conclude
with recommendations for improving education and outreach about the PADS Policy, both to potential
grant applicants and among NCI’s program staff and external grant reviewers, and how our findings may
be applicable to broader data sharing plans that are currently under development at NIH.
Background
Origin and development of NIH data sharing policies
In 1996, leaders of the international Human Genome Project (HGP) established a baseline of rapid, public
sharing of data in the biomedical sciences (International Human Genome Sequencing Organization,
1996). While the HGP was concerned primarily with genomic sequence data, the scope of scientific data
sharing has expanded in the decades since its completion. Beginning in 2006, the NIH and its National
Human Genome Research Institute (NHGRI) led the development of data sharing policies for a range of
research programs generating data beyond raw DNA sequences, including genetic variants, DNA
functional elements, and phenotypic and clinical data (Contreras, 2011; Contreras and Knoppers,
2018). Alongside these efforts, NIH instituted a policy in 2008 requiring that all publications resulting
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from NIH-funded research be made publicly available through the National Library of Medicine’s
PubMed Central database (National Institutes of Health (NIH), 2008).
In 2013, seeking to extend the benefits of scientific data sharing to the full range of nondefense
federally funded research, the Office of Management and Budget (OMB) enacted a sweeping Open Data
Policy that required federal agencies to make most government-funded data available in accessible,
modifiable and searchable formats, while taking into account individual privacy, confidentiality and
security considerations (Office of Management and Budget (OMB), 2013). Initiatives such as these are
aimed at the eventual development of an integrated "medical information commons" that will enable
broad data use and analysis in the diagnosis of disease, the search for cures and the improved understanding of human biology (Bollinger et al., 2019).
Numerous federal agencies, including NIH, responded to OMB’s ambitious directive. In 2014, NIH
revamped its policy for genomic data sharing (National Institutes of Health (NIH), 2014), and, in 2015,
NIH began planning a more sweeping overhaul of its trans-institute data sharing program (National
Institutes of Health (NIH), 2015). Most recently, in November, 2019, it released a draft Policy for Data
Management and Sharing (DMS) for public comment (National Institutes of Health (NIH), 2019). Like
the Cancer Moonshot PADS Policy, the draft DMS policy mandates that researchers seeking NIH funding
submit a data sharing plan as part of their grant applications. This plan would be reviewed by the funding
agency in evaluating the application, and compliance would be monitored during the course of the funded
research program.
The NCI Cancer Moonshot PADS Policy

In 2016, NCI, launched the Cancer Moonshot Program. The PADS Policy was an integral part of the
program and its announcement (Kaiser 2019a). The Policy addresses both open access to publications
resulting from Cancer Moonshot-funded research as well as the release of data generated by that research.
In the area of publication, the PADS Policy takes a more aggressive stance than the 2008 NIH Public
Access Policy, recommending (but not mandating) that research papers be deposited with PubMed
Central immediately upon publication (and preferably within four weeks after acceptance by a journal),
rather than one year after publication. The PADS Policy also encourages publication of papers under a
Creative Commons attribution license (CC BY 4.0) or via contribution to the public domain (CC 0).1
With regard to data, the PADS Policy states that “to the extent feasible,” data should be made publicly
available simultaneously with the publication of research results. Unlike prior NIH data sharing policies
that pertained primarily to genomic and related data, the PADS Policy defines data that must be shared as
any “recorded factual material commonly accepted in the scientific community as necessary to document
and support research findings in Publications” (National Cancer Institute (NCI), 2017a). This broad
definition thus encompasses all forms of clinical, pharmacological, demographic, analytical, survey, and
other data that might be collected or developed as part of a Cancer Moonshot project.
Because the scope of data encompassed by the PADS Policy is so broad, NCI offers applicants a degree
of flexibility in deciding how their research results and data will be released. Thus, the only firm
requirement of the PADS policy is that applicants for Cancer Moonshot funding submit to NCI a written
plan (a PADS plan) that describes a proposed process for making publications and data “immediately and
broadly available to the public” and, if such sharing is not possible, a justification for why it is not. NCI
also states that its review of grant funding proposals “will give funding priority to those Applicants that
submit an appropriate [PADS] [p]lan that ensures maximal sharing of [publications and data] arising from
the award.”

1
Creative Commons is a nonprofit organization that has developed a suite of self-executing licensing agreements for a wide range
of copyrightable works. Most Creative Commons licenses (designated as “CC”) permit the free dissemination, reproduction and
modification of licensed works. CC BY licenses require only that the user give attribution to the original source of the work.
Contributing a work to the public domain via a “CC 0” license requires the author to relinquish all rights to control or profit from
future uses of the work (Creative Commons, 2019).
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The PADS Policy lists the following “general elements” that each PADS plan “should, at a minimum,
address”:
Release of publications
1. How publications will be made immediately available to the public.
2. The methods through which the public including other researchers will locate and access the
publication.
3. Any anticipated limitations to the immediate and broad release of publications with an associated
justification.
Sharing of underlying primary data
1.
2.
3.
4.
5.
6.

The type of data that is expected to be generated by the research.
The data that will be shared.
Who will have access to the data.
The timing and the medium for immediate sharing of the data.
The methods through which the public including other researchers will locate and access the data.
Any anticipated limitations to the immediate and broad sharing of data with an associated
justification.

So, while the PADS Policy describes desirable features of submitted PADS plans (e.g., public release of
publications within four weeks after acceptance), these features are not mandatory requirements, but
merely recommendations.
Methods
To assess the degree to which successful Cancer Moonshot applicants addressed the requirements of the
PADS Policy in its first year of implementation, we identified all competing grant and cooperative
agreement applications that were funded under the Cancer Moonshot Program in fiscal year 2018 (n = 63)
through NCI’s website (NCI 2019) https://www.cancer.gov/research/key-initiatives/moonshot-cancerinitiative/implementation. These projects were funded under eight of the 12 different Research Initiatives
recommended by the Cancer Moonshot Blue Ribbon Panel. The Adult Immunotherapy Network initiative
funded the largest number of projects with 16. The remaining Research Initiatives represented were
Drivers of Childhood Cancer (11 funded projects), the Human Tumor Atlas Network (11), Symptom
Management (8), Pediatric Immunotherapy Network (6), Prevention and Early Detection (6), New
Enabling Cancer Technologies (4), and Hereditary Cancers (1). The principal investigator
(PI) identified in each funded Cancer Moonshot application was then contacted by email with a request
for the data sharing plan included with the funding application submitted to NCI.2
We received responses from 35 awardees3 representing all eight of the initiatives that funded proposals
in fiscal year 2018. To respect our anonymity agreements with the researchers who responded, we limit
2
In theory, this information could have been requested from NCI through a public records request under the Freedom of
Information Act (FOIA). For this study, we did not submit FOIA requests as our past experience with FOIA requests made to NIH for
other projects demonstrated that this process often involves significant delays. Moreover, we did not request amendments to grant
applications made in response to input from NCI staff. While the scope of our findings does not extend to the final plans that were the
product of informal and undocumented interaction with NCI staff after grant submission, we feel that there is value in assessing the
alignment between investigators’ initial plan submissions and NCI’s written policy statements. One important measure of the
success of a data sharing policy is how well the policy language, standing on its own, guides investigators in their efforts to follow the
requirements and aspirations of the policy statement. The clarity of policy language is critical as funding programs scale up to larger
and larger applicant pools, as it is not practical to assume that individualized guidance by program officers can be offered efficiently,
affordably or equitably by every funding agency to every applicant. Moreover, from a legal standpoint, an agency’s formal written
policies are important measures of its compliance with regulatory and statutory rulemaking and due process requirements.
3
Despite our high (>50%) response rate, we recognize that the self-selection of our respondents could have affected our findings.
However, we think it is unlikely that self-selection significantly biased our results toward either more or less conformity with the
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our reporting on the response rate within each research initiative to observing that we received plans from
about half of the funded projects in each initiative. No single research initiative was significantly
overrepresented in our overall response rate of approximately 55%. One initiative, Drivers of Childhood
Cancer, was an outlier to the otherwise consistent response rate across research initiatives. We received
three PADS plans from this group, out of the eleven funded projects.
The 35 responses came from 27 unique research institutions. Twenty-three institutions were awarded
one Cancer Moonshot grant, two were awarded two grants, and two were awarded three grants. Each plan
that we reviewed was submitted by a different PI. We received a total of 33 unique PADS plans4 and coded
each with respect to the manner in which it addressed, or did not address, the different elements described
in the PADS Policy.
We coded plans as satisfying a composite element of a PADS plan, for example, by identifying how
access to publications would be provided or data would be shared, when language within a plan was
associated with that element. This categorization was clearest when plans used—often word-for-word—
the guidance examples provided in the PADS Policy. But we also coded plans as satisfying required plan
elements when there were specific descriptions of other relevant actions that supported the particular
element. We coded plans as representing a complete PADS plan when the submitted text addressed the
required plan elements for both sharing of publications and underlying data. The text of each plan was
manually parsed sentence by sentence and compared by the authors against the language from the PADS
Policy that describes required elements and provides guidance examples.
Results
Overall structure of submissions

Among the 33 submitted plans that we reviewed, only 17 had substantial provisions related to both
publication and data sharing, which would qualify them as PADS plans. In 13 of these, the plan was
labeled a “Public Access and Data Sharing Plan” or used headings or other language to identify itself as a
PADS plan. Every plan that addressed publication access also addressed data sharing. There were 8
additional plans that did not contain a section on open access publication, but which did provide
significant information about data sharing, including guidance examples derived from the PADS Policy.
Another 8 plans did not appear to address the PADS Policy elements for either publications or data
sharing.
Highlighting the overlap between older NIH policies and the new Cancer Moonshot PADS Policy, 9
of the plans that we classified as partially or fully addressing the PADS Policy elements included
references to only non-Cancer Moonshot NIH policies. The most common policies referenced were
the 2003 NIH Statement on Sharing Research Data (11) (NIH 2003) and the 1999 NIH Research Tools
Policy (12) (NIH 1999), which appeared in five and six plans, respectively. NIH’s 2008 Public Access
Policy (4) (NIH 2008) was mentioned by one plan in this group.
Publication sharing

Under the PADS Policy, applicants are required to identify the methods through which the public,
including other researchers, will be able to locate and immediately access publications generated by the
grant-funded research. Of the 33 funded FY18 PADS plans that we reviewed, 16 did not engage with the

PADS Policy standards, given that we did not identify our specific research questions at the time that investigators’ PADS plans were
solicited and that there was a high degree of variability in the plans that we received. If there is self-selection bias in our results, we
expect that would be the product of a higher response rate among investigators who thought they had been largely successful in
following the PADS Policy and, therefore, were comfortable sharing their PADS plan with other researchers. If that was the case, it
would make our findings more remarkable because the low rate of adherence to the PADS Policy requirements that we see here
would be an overstatement of how well PADS plans from fiscal year 2018 conformed to the new Cancer Moonshot PADS Policy.
4
Two responses were submitted by Coordinating Centers, which indicated that PADS plans would be developed by the individual
research projects for which they acted as coordinator.
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Primary Features of Moonshot PADS
Plan Submissions
18
16
Number of Plans

14
12
10
8
6
4
2
0
address OA publicaon and
data sharing

address only data sharing

address neither

Figure 1 . Primary features of PADS plan submissions.
PADS publication requirements. Two others mentioned publication without referencing the PADS Policy
or mentioning the term “Moonshot.” One wrote of a preference for publishing in open access journals so
long as the journal “commit[s] to rigorous peer review.” The other simply stated that the researchers would
comply with the PubMed Central deposit requirement under the 2008 NIH Public Access Policy (which,
as noted above, includes a 12-month delay in publication release that is inconsistent with the recommendations of the PADS Policy).
Among the 15 plans that more fully addressed the PADS Policy elements relating to publication,
11 inserted verbatim, or nearly so, the 3 relevant guidance examples from the PADS Policy, including the
commitment to deposit publications in PubMed Central within 4 weeks after acceptance by a journal.
Another stated that investigators would “consider” publishing in open access journals “whenever
possible.” All 15 plans that addressed the PADS Policy publication elements included a statement that
publications would be deposited in PubMed Central (as required since 2008).
Only three plans stated that the investigators would pay open access fees to ensure that publications
would be made available on an open access basis. And only one of these noted that the grant proposal
included a budget request for funds to support open access fees for accepted publications, charges that the
PADS Policy explicitly designates as permissible budget items (we did not have access to the actual
budget submissions or awards associated with these applications).
As noted above, the PADS Policy permits applicants to describe any proposed “limitations” on
publication sharing. Nine of the 15 plans that included publication sharing provisions used language
that limited unrestricted, immediate access to publications. Two of these expressly referred to limitations
imposed by journal policies. For example, one stated, “After satisfying journal or society embargo
periods, publications will be made publicly available immediately.” The same plan also committed to
publish under Creative Commons or other public domain licensing “when not restricted by journal
policy.” Two of the plans state that they will publish under an open access license “whenever possible,”
and five use aspirational but noncommittal language about publication in open access journals. For
example, these plans state that researchers “will seek” or “aim” or “consider” publication of results in open
access journals. And one plan simply “pledge[d] support for open access publishing policies.”
NCI admitted that there was some confusion among grantees regarding the PADS Policy’s open access
publication requirements, as well as resistance by publishers to allowing immediate release of published
articles on PubMed Central (Fleming, 2019). To address these issues, NCI engaged in discussions with
several major scientific publishers to explain the PADS Policy requirements, while at the same time
reminding grantees that “It is imperative that all investigators supported by your Cancer Moonshot grant
are aware of [the PADS] policy and are in compliance with the publication and data sharing plan of your
award” (Fleming, 2019).
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Data sharing

Twenty-five PADS plans contained specific provisions related to methods and means for sharing data. The
PADS Policy asks investigators to specify the “medium” for data sharing. For this required plan element,
NCI offers a guidance example that data will be made available through a repository such as Genomic
Data Commons, the Database of Genotypes and Phenotypes (dbGaP), The Cancer Imaging Archive
(TCIA), or a non-NIH repository that provides data access controls consistent with the PADS Policy.
Twenty-two of the 25 plans addressing data sharing named at least one specific repository. The most
common commitment, which was made by three plans, was to deposit data in dbGaP. In addition to two
mentions each of the NCI Genomic Data Commons and the National Center for Biotechnology
Information Gene Expression Omnibus, 13 other individual databases were mentioned, including
3 proprietary repositories maintained by the applicants.
Notably, more than one-third (9) of the plans that included data deposit provisions did not commit to use
a particular database. The most general statement was that data would be deposited in “standard and freely
available databases.” Another plan pledged to deposit data in an “appropriate” repository to be selected by
the project steering committee. The most common approach, taken by six of the plans, was to reference one
or more of the repositories named in the PADS Policy guidance example as options, but without committing
to any specific repository. Finally, one plan indicated that the investigators intended to develop a new data
sharing platform as part of the proposed project. This plan provided some platform specifications including
user registration and authentication, but most of the supporting details discussed data formatting.
The Cancer Moonshot program anticipated that data would be shared via a federally managed National
Cancer Data Ecosystem (Cancer Moonshot Blue Ribbon Panel Report, 2016). To this end, some Cancer
Moonshot funding announcements indicated that data sharing and coordination would be required with
NIH data repositories including the Cancer Epidemiology Data Repository (CEDR) (Department of
Health & Human Services (HHS), 2017). Yet, as of this writing, the CEDR data repository has still not
been launched, leaving some grantees unable to satisfy the commitments made in their PADS plans.
Responding to the OMB directive of 2013, the NCI PADS Policy also asks applicants to specify how
their plans would address “the methods through which the public including other researchers will locate
and access the data.” Among the 17 plans that addressed this element, the most common offerings were
direct sharing when data is requested by another researcher (9 plans), and a commitment in 8 plans to make
presentations at conferences and other scientific gatherings. In addition, 7 plans stated that researchers
would publicize information about their Cancer Moonshot research on a public website, with 6 of these
plans making reference to the website including information about how to access or request data.
Discussion
Overall assessment

The above findings suggest that, during the first year of its effectiveness, there were significant gaps in the
implementation of the Cancer Moonshot PADS Policy. Though the submission of a PADS plan addressing
both publication and data sharing was required in all applications for Cancer Moonshot funding, nearly
half of the 33 PADS plans from funded grant applications that we reviewed did not engage meaningfully
with both prongs of the PADS Policy, and 8 did not mention any of the PADS Policy elements for
publications or data sharing.
Sixteen plans did not mention open access publication. Of those that did, several were cursory and
nonspecific. In a similar vein, though the PADS Policy asked applicants to specify how their plans would
address “the methods through which the public including other researchers will locate and access the
data,” nearly half did not, and most of those that mentioned this policy element did so without making
definitive, detailed commitments.
In terms of data repositories, applicants mentioned a total of 16 different databases in which data would
be deposited, including 3 proprietary repositories. We are aware of no plan by NCI or others to enable the
interoperability or long-term stewardship of these data repositories. Such a diverse array of independent
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data repositories is not likely to facilitate the efficient public utilization of data generated under the Cancer
Moonshot Program (Contreras and Reichman, 2015; Sherkow, 2018).
As discussed above, one-third of the plans submitted to NCI referenced at least one earlier NIH data
sharing and publication policies from 1999, 2003, and 2008, even when the PADS plan superseded the
requirements of these earlier policies. This suggests that these plans were, at least to some degree, copied
from earlier grant applications that pre-dated the PADS Policy. In fact, a majority of the plan language that
we reviewed appeared to originate from grant applications that were not subject to the PADS Policy.
Analysis

The degree to which successful Cancer Moonshot grantees—many of which were experienced research
teams from leading institutions—omitted reference to the PADS Policy suggests that grant applicants
were uncertain about the requirements of the PADS Policy, or did not appreciate that the PADS Policy
would apply to their research. We suspect that some terms in the PADS Policy, such as “CC BY 4.0” and
“public domain,” which may be familiar to those in the policy community, may be less familiar to
researchers accustomed to publishing their work in traditional scholarly journals and to grant managers
and science writers who may have been asked to assist with the preparation of this portion of the Cancer
Moonshot applications. Journals themselves may be unfamiliar with the aggressive publication sharing
principles of the Cancer Moonshot Program (Kaiser, 2019b). While Cell and Science journals have now
adopted special open access provisions for Cancer Moonshot-funded articles, others, such as Nature, will
consider requests on a case by case basis only (Kaiser, 2019b). And beyond these few top-tier journals, the
vast majority of medical and scientific journals have no provision for rapid release of Moonshot-funded
articles.
Likewise, though the precepts of scientific data sharing have been acculturated among researchers in
genomics and related fields, they may be less familiar to researchers seeking Cancer Moonshot funding in
fields such as oncology, surgery, pharmacology, and social sciences. Moreover, as demonstrated by the
unavailability of repositories for nongenomic data types, such as clinical, social, and behavioral data, it
appears that NCI did not adequately prepare for the rollout of such an ambitious data sharing program
across multiple scientific disciplines.
Given the significant changes to existing data sharing practices that were introduced by the PADS
Policy, the prominence with which the policy was announced by NCI, and the likely inexperience of many
potential Cancer Moonshot grant applicants with the intricacies of publication and data sharing policy
(including, e.g., Creative Commons licensing), significant NCI planning, training, and educational
outreach to the applicant community might have been expected with regard to the PADS Policy. Yet
little was offered in this regard. Neither the PADS Policy nor NCI’s briefing materials explain how the
requirements and recommendations of the PADS Policy differ from prior NIH publication or data sharing
policies, requiring researchers accustomed to working within existing frameworks to assess policy
differences on their own. In the NCI-sponsored webinar announcing and explaining one of the FY18
Cancer Moonshot grant opportunities, of 17 slides that were presented, only one-half of one slide included
information about publication and data sharing, and this simply referenced an existing NCI genomics
repository (GDC) and the still pending epidemiology data repository mentioned above (CDER) (National
Cancer Institute (NCI), 2017b).5 Notably, the slides describing the four “Goals” and five “Aims” of the
Cancer Moonshot program did not mention data or publication sharing, or the PADS Policy, at all
(National Cancer Institute (NCI), 2017b). Likewise, neither publication/data sharing not the PADS Policy

5

Slide 10 contains the following text:
1. Required data/resource sharing with existing NIH resources.
1.1. Submit a Pubic [sic] Access and Data Sharing Plan.
1.1.1. Genomic Data Commons (GDC).
1.1.2. Cancer Epidemiology Data Repository (CDER).
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are mentioned in the NCI FAQ relating to this funding mechanism (National Cancer Institute (NCI),
2017c).
As a result, we suspect that NCI’s aspirational data sharing initiatives, conceived at the highest levels of
the Institute, may not have been adequately disseminated within NCI. In particular, we believe that more
practical education regarding the PADS Policy, and its publication/data sharing mechanisms and
expectations, should have been offered to NCI program officers overseeing Cancer Moonshot funding
mechanisms, as these individuals are often the first line of inquiry when investigators are faced with
complex new application requirements. In addition, it is possible that NCI’s Cancer Moonshot study
sections, comprised of volunteer researchers from across the country, were also unfamiliar with the
intricacies of the PADS Policy. In order for these individuals, as well as the members of NCI’s Council,
which ultimately approves all grant funding, to assess grant applications in a manner that is consistent with
NCI policy, additional training and guidelines for the review of applications subject to the PADS Policy
would have been helpful for this new area of “funding priority.”
Broader implications

The PADS Policy, in an effort to offer flexibility to researchers dealing with a broad spectrum of data
types, permits grant applicants to submit a PADS plan for review and assessment by NCI. However, as
shown above, this degree of flexibility was not effective when applicants were inadequately apprised of
the importance or details of the PADS Policy, and when NCI itself had not adequately considered the
mechanisms for sharing of data types beyond traditional genomic and associated phenotypic data.
Similar to the PADS Policy, NIH’s new draft Policy for DMS also relies on applicant-generated data
sharing plans rather than concrete data sharing requirements. This reliance on applicant-generated plans,
rather than concrete agency mandates, could result in plans that overlook or undervalue data sharing, a
concern that we share with other commenters on NIH’s draft DMS Policy (Sim et al., 2020). By the same
token, without concrete guidance from NIH, it is not reasonable to expect individual research teams to
formulate and deploy adequate data sharing plans for novel data types. Moreover, this individualized plan
approach, by pushing the work of developing data sharing practices for diverse data types onto
investigators rather than funding agencies, eliminates any prospect of uniform and interoperable data
resources that are usable broadly by the research community. If data sharing migrates from the centralized
repositories currently operated by NIH (through the National Center for Biotechnology Information) in
the genomics arena to a multitude of fragmented institutional repositories, the overall benefit to the
scientific community is likely to diminish (Contreras and Reichman, 2015; Sherkow, 2018).
Our findings suggest a need for more robust planning, communication, and education regarding
publication and data-sharing requirements. Offering concrete guidance and expectations regarding the
logistics and practicalities of sharing both genomic and nongenomic data is critical. The need for training
is urgent, both with respect to potential grant applicants and also the many program officers throughout
NIH who will be expected to explain and manage these new policies. These points will become
particularly important as data sharing requirements move from the relatively circumscribed realm of
genomics and related fields to the vast array of health science disciplines covered by NIH-funded research
with the eventual goal of forming an integrated "medical information commons" (Bollinger et al., 2019).
For researchers in these disciplines, the aggressive data sharing precepts that originated with the HGP may
be both unfamiliar and counterintuitive, and significant acculturation may be required in order to ensure
the successful implementation of these data sharing practices across the scientific community.
Conclusion
NCI’s Cancer Moonshot PADS Policy was adopted with the ambitious goal of “accelerat[ing] cancer
research by enhancing data sharing and making evidence-based approaches to cancer therapy more
broadly available to patients.” To this end, NCI’s PADS Policy required the submission of a PADS plan
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with each funding application under the Cancer Moonshot Program, and emphasized the “funding
priority” would be given to applicants that ensured “maximal sharing” of resulting publications and data.
Yet our review of 33 PADS plans submitted with funded FY18 Cancer Moonshot applications reveals
that few fully addressed the requirements of the PADS Policy. Many, in fact, appeared to rely on pre-PADS
language taken from prior grant applications that referenced NIH policies dating from 1999 to 2003.
Moreover, there is little evidence that NCI evaluated grant applications based on their PADS plans as
submitted without subsequent guidance from NCI program staff, given how many were funded after
submitting partial information about publication and data sharing plans.
We believe that these gaps arose from a combination of insufficient planning, education, and outreach
by NCI concerning its PADS Policy, both with respect to potential grant applicants and NCI’s program
staff and external grant reviewers. Accordingly, we recommend that NCI undertake improved planning
and educational efforts regarding the importance and implementation of the PADS Policy for relevant
Cancer Moonshot program officers and study section members. And once the applicant community is
adequately apprised of the data and publication sharing requirements of the PADS Policy, we hope that
NCI diligently enforces its “funding priority” to select applications that ensure “maximal sharing” of
publications and data.
We believe that our findings and recommendations are relevant beyond NCI and the Cancer Moonshot,
as NIH is currently considering the adoption of a similar plan-based data sharing policy that would apply
across all NIH institutes and centers. Accordingly, we would urge NIH to consider the recommendations
made above with respect to its draft DMS Policy.
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